Related Experiment Videos
A two-year crossover therapeutic trial with halofenate and clofibrate
The American Journal of the Medical Sciences
|November 1, 1976
Summary
Halofenate and clofibrate effectively lower triglycerides and cholesterol in Type IV hyperlipoproteinemia patients. Saliva secretor status influences cholesterol response, and halofenate shows promise for patients with high uric acid levels.
Area of Science:
- Pharmacology
- Metabolic Disorders
- Clinical Trials
Background:
- Type IV hyperlipoproteinemia is characterized by elevated plasma triglycerides.
- Effective management strategies for hyperlipoproteinemia are crucial for cardiovascular health.
- Understanding genetic and physiological factors influencing drug response is important.
Purpose of the Study:
- To compare the efficacy of clofibrate and halofenate in treating Type IV hyperlipoproteinemia.
- To investigate the influence of ABO blood group antigen secretion on drug response.
- To assess the effects of these drugs on serum lipids, bilirubin, and uric acid levels.
Main Methods:
- A two-year, double-blind, crossover trial involving twelve patients with Type IV hyperlipoproteinemia.
- Drug serum levels were monitored to ensure compliance.
- Analysis of lipid profiles, bilirubin, uric acid, and correlation with secretor status.
Main Results:
- Both clofibrate and halofenate demonstrated equal effectiveness in reducing plasma triglycerides and cholesterol.
- Secretors of ABO blood group antigens showed a more significant hypocholesterolemic response compared to nonsecretors.
- Clofibrate increased low-density lipoprotein cholesterol, while both drugs lowered bilirubin and uric acid levels, with halofenate having a stronger hypouricemic effect.
Conclusions:
- Clofibrate and halofenate are equally effective in managing hypertriglyceridemia and hypercholesterolemia in Type IV hyperlipoproteinemia.
- ABO secretor status is a predictive factor for hypocholesterolemic response.
- Halofenate's potent hypouricemic effect makes it a potentially valuable therapeutic option for hyperlipoproteinemic patients with hyperuricemia.